Table 2. Treatments characteristics.
| Characteristics | Median (min-max) or Nb(%) |
|---|---|
| Number of patients | 113 (100) |
| Radiotherapy | |
| Dose (Gy) | 45 |
| Pelvic irradiation | 113 (100) |
| Para-aortic irradiation | 13 (11.5) |
| Sequential lymph node boosts | 45 (39.8) |
| Median boosts doses (Gy) | 10 (7.2–14) |
| Concurrent chemotherapy Yes | 113 (100) |
| No | 0 (0) |
| Number of chemotherapy courses | 6 (3–7) |
| Chemotherapy type Cisplatine | 102 (90.3) |
| Carboplatine | 6 (5.3) |
| Both | 5 (4.4) |
| Brachytherapy parameters | |
| MRI guided | 113 (100) |
| HR-CTV volume (cm3) | 21.3 (9.9–79.0) |
| HR-CTV D90 (Gy) | 38.2 (17.8–50.5) |
| TRAK | 1.73 (0.67–2.43) |
| Use of interstitial needles | 10 (8.8) |
| Overall treatment time (days) | 47 (38–62) |
HR-CTV: high-risk clinical target volume; MRI: Magnetic Resonance Imaging; TRAK: Total reference air Kerma.